Nuvation Bio Inc. (NUVB) and Eisai have received validation from the European Medicines Agency for their drug Taletrectinib. This regulatory approval marks a significant milestone for the biotech collaboration.
- EMA validation for Taletrectinib
- Collaboration between Nuvation Bio and Eisai
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.
Share this article